A Placebo Controlled Study Evaluating Efficacy and Safety of Medication in Patients with Bipolar Disorder
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
150
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
La Jolla, California, United States
Change from baseline scores at Week 8 for the Montgomery-Asberg Depression Rating Scale (MADRS)
Time frame: 8 Weeks
Change from baseline scores at Week 8 for the Hamilton Depression Rating Scale (HAMD-17, HAMD-31, Bech Melancholia Scale (BMS), and HAMD - Item 1), Clinical Global Impressions of Severity (CGI-S) and Improvement (CGI-I).
Time frame: 8 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Santa Ana, California, United States
GSK Investigational Site
Marietta, Georgia, United States
GSK Investigational Site
Terre Haute, Indiana, United States
GSK Investigational Site
Shreveport, Louisiana, United States
GSK Investigational Site
Saint Charles, Missouri, United States
GSK Investigational Site
Princeton, New Jersey, United States
GSK Investigational Site
New York, New York, United States
...and 10 more locations